Preparat Gaziva® stanet dostupen‌‌ dlya terapii patsientov s khronicheskim limfotsitarnym leykozom

作者: <a target="_blank" href="https://journals.rcsi.science/1815-1434/search/authors/view?firstName=-&amp;middleName=&amp;lastName=-">- -
期: 卷 17, 编号 2 (2015)
页面: 7
栏目: Articles
URL: https://journals.rcsi.science/1815-1434/article/view/26987
ID: 26987

如何引用文章

全文:

Новый препарат компании «Рош» Газива® (обинутузумаб) для терапии ранее не леченных пациентов станет доступен на российском рынке с сентября 2015 г.

##article.viewOnOriginalSite##

Goede V et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. NEJM 2014; 370: 1101-10. doi: 10.1056/NEJ- Moa1313984
Lamanna N et al. Chronic Lymphocytic Leukemia and Hairy-Cell Leukemia. Cancer Management. Available at: http://www.cancernet-work.com/cancer-management/chronic-lymphocytic-leukemia-and-hairy-cell-leukemia
Ferlay J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49 (6): 1374-403. doi: 10.1016/j.ejca.2012.12.027
GLOBOCAN Europe (2012). Estimate cancer incidence, all ages: both sexes. Available at: http://globocan.iarc.fr/old/summary_table_pop-html.asp?selection=62968&title=Europe&sex=0&type=0&win-dow=1&sort=0&submit=%C2%A0Execute
LOBOCAN Europe (2012). Estimate cancer mortality, all ages: both sexes. Available at: http://globocan.iarc.fr/old/summary_table_pop-html.asp?selection=62968&title=Europe&sex=0&type=1&win-dow=1&sort=0&submit=%C2%A0Execute
Goede V et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia 2015: 1-3. doi: 10.1038/leu.2015.14